Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? – experience of the Brugmann hospital in Brussels

BACKGROUND: 131-iodine ((131)I) administration after surgery remains a standard practice in differentiated thyroid cancer (DTC). In 2014, the American Thyroid Association presented new guidelines for the staging and management of DTC, including no systematic (131)I in patients at low-risk of recurre...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thyroid Res
Hlavní autoři: Iconaru, Laura, Baleanu, Felicia, Taujan, Georgiana, Duttmann, Ruth, Spinato, Linda, Karmali, Rafik, Bergmann, Pierre, Hambye, Anne-Sophie
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7488699/
https://ncbi.nlm.nih.gov/pubmed/32944083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13044-020-00089-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky